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Immunophilin, FK506-binding protein 12 (FK506BP), is a receptor protein for the immunosuppressive drug FK506
by the FK506BP/FK506 complex. However, the precise function of FK506BP in inflammatory diseases remains
unclear. Therefore, we examined the protective effects of FK506BP on atopic dermatitis (AD) in tumor necrosis
factor-a (TNF-a)/interferon-g (IFN-g)-induced HaCaTcells and 2,4-dinitrofluorobenzene-induced AD-like dermatitis
in Nishiki-nezumi Cinnamon/Nagoya (NC/Nga) mice using a cell-permeable PEP-1-FK506BP. Transduced PEP-1-
FK506BP significantly inhibited the expression of cytokines, as well as the activation of NF-kB and mitogen-
activated protein kinase (MAPK) in TNF-a/IFN-g-induced HaCaT cells. Furthermore, topical application of PEP-1-
FK506BP to NC/Nga mice markedly inhibited AD-like dermatitis as determined by a histological examination and
assessment of serum IgE levels, as well as cytokines and chemokines. These results indicate that PEP-1-FK506BP
inhibits NF-kB and MAPK activation in cells and AD-like skin lesions by reducing the expression levels of cytokines
and chemokines, thus suggesting that PEP-1-FK506BP may be a potential therapeutic agent for AD.
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INTRODUCTION
Atopic dermatitis (AD) is a common pruritic and chronically
relapsing inflammatory skin disease that is steadily increasing
in prevalence. Endogenous and exogenous factors have a role
in the manifestation of AD, which seriously affects patients,
their families, and socioeconomic aspects of life (Homey
et al., 2006). With lifetime prevalence rates of 10–20%
in children and 1–3% in adults, AD is a major worldwide
public health problem (Schultz-Larsen and Hanifin, 2002).
The wide variations in prevalence identified in countries with
an ethnically similar population suggest that environmental
factors determine the expression of AD (Williams et al.,
1999). Skin lesions of AD are well characterized by infil-
trating lymphocytes, monocytes/macrophages, eosinophils,
and fully granulated mast cells (Scoter, 1989; Uehara et al.,
1990). In 1957, Nishiki-nezumi Cinnamon/Nagoya (NC/Nga)
mice were established as an inbred strain from Japanese
fancy mice. When NC/Nga mice are kept in an air-
uncontrolled conventional circumstance, they spontaneously
develop AD-like dermatitis. However, when kept in specific
pathogenic-free conditions, these mice remain normal
and healthy (Matsuda et al., 1997; Watanabe et al., 2002).
The application of 2,4-dinitrofluorobenzene (DNFB), evokes
contact hypersensitivity reaction in mice (Tomimori et al.,
2004). Furthermore, AD-like dermatitis found in NC/Nga
mouse models is accompanied by elevated serum IgE levels,
increased expression of Th2 cytokines, eosinophil accumula-
tion in the lesions, and frequent scratching behavior, which
are characteristic features of human AD (Matsuda et al.,
1997; Vestergaard et al., 1999, 2000).
FK506-binding proteins (FK506BPs) belong to a family of
immunophilins named for their ability to bind immunosup-
pressive drugs. FK506BPs can be associated with chaperones
and constitute a major part of receptor complexes. FK506BP
12 is a small peptide with a single FK506BP domain and a
molecular size of 12 kDa. FK506BP is involved in multiple
biological processes, which involve binding to rapamycin
and formation of a complex of rapamycin-mediated phos-
phatidylinositol 3-kinase/Akt/mammalian target of rapamycin
downstream signal transduction, which is the major mechan-
ism for applying rapamycin in tumor treatment (Schreiber,
1991; Snyder and Sabatini, 1995; Cameron et al., 1997;
Schiene-Fischer and Yu, 2001).
Protein transduction is an established means of delivering
proteins both in vitro and in vivo by protein transduction
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domains or cell-penetrating peptides. Although the exact
mechanism of transduction is unclear, many studies have
demonstrated that protein transduction allows the delivery of
therapeutic proteins in vitro and in vivo (Morris et al, 2001;
Wadia and Dowdy, 2002; Eum et al., 2004; Choi et al., 2006;
An et al., 2008).
In this study, we demonstrate that a PEP-1–FK506BP
fusion protein can be directly transduced into HaCaT cells
and markedly inhibits the expression of cytokines, as well
as the activation of NF-kB and mitogen-activated protein
kinase (MAPK) in HaCaT cells. In addition, topical applica-
tion of PEP-1-FK506BP to NC/Nga mice significantly inhibits
AD as determined by a histological examination and serum
IgE levels. Therefore, we suggest that topical application
of the PEP-1–FK506BP fusion protein may be a potential
therapeutic agent for AD.
RESULTS
Purification and transduction of the PEP-1–FK506BP fusion
protein into HaCaT cells
A cell-permeable expression vector, PEP-1-FK506BP, con-
taining the human FK506BP cDNA and PEP-1 peptide
was constructed. After purification of PEP-1-FK506BP, its
intracellular delivery into HaCaT cells was confirmed by
direct fluorescence analysis (Figure 1a). PEP-1-FK506BP was
efficiently transduced into cells, whereas no fluorescence
signals were evident in negative control cells and in cells
treated with control FK506BP. To exclude the possibility that
cell fixation with paraformaldehyde may have affected PEP-1-
FK506BP transduction by direct fluorescence, FITC-conjugated
PEP-1-FK506BP was transduced into unfixed and fixed HaCaT
cells. The intracellular distribution of the PEP-1-FK506BP
fluorescence signal in unfixed cells was similar to that in fixed
cells. These results indicate that cell fixation with paraformal-
dehyde is not required for PEP-1-FK506BP transduction.
In addition, the transduction efficiency of PEP-1-FK506BP
was confirmed by flow cytometry of HaCaT cells (Figure 1b).
Various concentrations (0.1–1 mM) of PEP-1-FK506BP were
added to HaCaT cells in culture for 60minutes, and levels
of transduced proteins were measured by flow cytometry.
The fusion proteins were transduced into HaCaT cells in a
concentration-dependent manner.
To clarify the subcellular localization of transduced
proteins into cells, nuclear and cytosolic fractions were
prepared from cells transduced with PEP-1-FK506BP and
then analyzed by western blotting using anti-histidine, anti-
actin, and anti-poly (ADP-ribose) polymerase antibodies.
As shown in Figure 1c, PEP-1-FK506BP was detected in the
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Figure 1. Transduction of PEP-1–FK506BP fusion proteins into HaCaT cells. (a) After FITC-labeled PEP-1-FK506BP and control FK506BP fusion
proteins (0.5 mM) were transduced into HaCaT cells, cells were washed twice with trypsin-EDTA, PBS, and were immediately observed by fluorescence
microscopy. Lanes are as follows: lane 1, control cells; lane 2, cells treated with FK506BP; lane 3, unfixed cells treated with PEP-1-FK506BP; lane 4, fixed cells
treated with PEP-1-FK506BP. Bar¼ 50 mm. (b) Uptake of PEP-1–FK506BP fusion proteins assessed by flow cytometry. (c) Subcellular localization of PEP-1-
FK506BP. The nuclear and cytosolic extracts were prepared from transduced cells and analyzed by western blotting. Lanes are as follows: lane 1, cytosolic
fraction; lane 2, nuclear fraction. FK506BP, FK506-binding protein 12; PARP, poly (ADP-ribose) polymerase; PBS, phosphate-buffered saline.
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nuclei and in the cytoplasm of transduced cells. However, it
was distributed more in the cytosol than in the nuclei.
Inhibitory effects of PEP-1-FK506BP on TNF-a/IFN-c-induced
activation of NF-jB and MAPK activation, and cytokine/
chemokine expression in HaCaT cells
To determine the effect of transduced PEP-1-FK506BP on tumor
necrosis factor-a (TNF-a) (10ngml1)/IFN-g (10ngml1)-in-
duced activation of NF-kB, HaCaT cells were incubated
for 15minutes with TNF-a/IFN-g in the presence or absence
of PEP-1-FK506BP. Nuclear extracts from TNF-a/IFN-g-induced
cells were analyzed using an electromobility shift assay.
Transduced PEP-1-FK506BP decreased the TNF-a/IFN-g-in-
duced DNA-binding activity of NF-kB (Figure 2a). Next, the
regulatory effect of PEP-1-FK506BP on the TNF-a/IFN-g-induced
signal cascade of NF-kB activation was examined. PEP-1-
FK506BP inhibited TNF-a/IFN-g-induced IkBa phosphorylation
and degradation in cells (Figure 2b).
The MAPK signaling cascades are involved in the
activation of NF-kB (Dhar et al., 2002). Appropriately, an
experiment investigated the regulatory effect of PEP-1-
FK506BP on MAPKs p38 activity, c-Jun N-terminal kinase
(JNK), and extracellular signal-related kinase. To examine
the effect of PEP-1-FK506BP on TNF-a/IFN-g-induced MAPK
activation, HaCaT cells were incubated for 15minutes with
TNF-a/IFN-g in the presence or absence of PEP-1-FK506BP
and then analyzed by western blot analysis using phos-
pho-specific antibodies against MAPKs (Figure 2c). PEP-1-
FK506BP decreased TNF-a/IFN-g-induced phosphorylation of
p38 and JNK in a dose-dependent manner, whereas extra-
cellular signal-related kinase levels were not changed.
Various cytokines and chemokines such as TNF-a, IL-1b,
IL-6, thymus and activation-regulated chemokine (TARC),
macrophage-derived chemokine (MDC), and chemokine
(C-X-C motif) ligand (CXCL) might be involved in inflamma-
tion and AD (Imai et al., 1997; Vestergaard et al., 1999;
Sandoval-Lopez and Teran, 2001; De Vry et al., 2005;
Murakawa et al., 2006). Accordingly, we examined the
effects of the PEP-1–FK506BP fusion protein on cytokine and
chemokine production in TNF-a/IFN-g-stimulated HaCaT
cells. Cytokine and chemokine levels increased after treat-
ment with TNF-a/IFN-g, whereas PEP-1-FK506BP markedly
inhibited the TNF-a/IFN-g-induced mRNA expression of
various cytokines and chemokines (Figure 2d). We further
investigated the effect of PEP-1-FK506BP on the expression of
TNF-a/IFN-g-stimulated HaCaT cells. Cells were incubated
for 24 hours with TNF-a/IFN-g in the presence or absence
of PEP-1-FK506BP, and then culture supernatants were
analyzed for secretion levels of cytokine and chemokine
protein by ELISA. PEP-1-FK506BP decreased TNF-a/IFN-g-
induced protein expression of cytokine and chemokine in a
dose-dependent manner (Figure 2e). These results were
consistent with the suggestion that PEP-1-FK506BP inhibits
TNF-a/IFN-g-induced NF-kB and MAPK activation, as well as
various cytokine/chemokine expression levels. Thus, the
inhibition of cytokines and cytokine expressions may con-
stitute an effective previously unreported therapeutic strategy
for the treatment of AD.
Effect of transduced PEP-1–FK506BP fusion proteins
on DNFB-induced NC/Nga mice
Atopic dermatitis-like skin lesions were induced in NC/Nga
mice using multiple topical applications of DNFB for 5 weeks
(Figure 3a). However, the topical application of PEP-1-
FK506BP to mice for 1 hour after DNFB application markedly
inhibited DNFB-induced AD (Figure 3b).
To examine the role of PEP-1-FK506BP in inhibiting AD,
PEP-1-FK506BP was topically applied to DNFB-treated mice
skin. The skin was stained with hematoxylin and eosin
and toluidine, and examined using an optical micro-
scope. Figure 4a shows the representative results of histo-
logical analyses of the skin lesions of DNFB-treated mice.
At 5 weeks, hyperplasia and thickening of the epidermis
were evident and cell infiltration was more marked in
NC/Nga mice than in control mice. PEP-1-FK506BP transduc-
tion significantly inhibited DNFB-induced skin lesions. In
addition, the changes were markedly inhibited by protopic, a
reference drug. However, control FK506BP showed little to no
effect on DNFB-induced skin lesions. Mast cell infiltration was
also decreased in PEP-1-FK506BP-treated mice (Figure 4b).
In NC/Nga mice, serum levels are closely correlated with
the clinical severity of dermatitis. Therefore, serum levels
were measured in DNFB- and PEP-1-FK506BP-treated mice.
DNFB-treated mice showed significantly enhanced serum IgE
levels than did control mice. Increased serum IgE levels
were lower in PEP-1-FK506BP- and protopic-treated mice. In
addition, combined PEP-1-FK506BP- and protopic-treated
mice showed more markedly decreased serum IgE levels.
However, control FK506BP had little to no effect on serum
IgE levels (Figure 5).
The effect of PEP-1-FK506BP on cytokine mRNA expres-
sion levels in the same conditions was examined by reverse
transcription-PCR. Cytokine levels were increased by treat-
ment with DNFB alone. PEP-1-FK506BP significantly re-
duced the production of TARC, MDC, IL-4, and IL-5, whereas
control FK506BP had minimal effects on the levels of these
cytokines (Figure 6). These results were consistent with the
view that PEP-1-FK506BP can prevent the development of
dermatitis in NC/Nga mice.
DISCUSSION
These results demonstrate that transduced PEP-1-FK506BP
significantly inhibits the expression of cytokines, as well as
the activation of NF-kB and MAPK in HaCaT cells.
Furthermore, topical application of PEP-1-FK506BP to
NC/Nga mice markedly inhibited AD-like skin lesions as
determined by a histological examination, assessment of
serum IgE levels, and expression levels of cytokines. These
results implicate PEP-1-FK506BP to be a potential therapeutic
agent for AD.
FK506BPs are a family of immunophilins that were named
for their ability to bind immunosuppressive drugs. To date, 15
mammalian FK506BPs have been found; most are expressed
in the brain. Among the FK506BPs, FK506BP12 has been
particularly well characterized (Guo et al., 2001; Harrar
et al., 2001). In this study, a cell-permeable PEP-1–FK506BP
fusion protein was constructed and used to investigate the
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protective effects of PEP-1-FK506BP against AD to clarify
the biological function and molecular mechanism of the
FK506BP protein in AD. Many studies, including those
performed by our group, have demonstrated that protein
transduction is an effective protein therapeutic strategy.
However, it has been claimed that cell fixation should be
avoided in studies of protein transduction into cells because
protein transduction domains are an artifactual redistribution
caused by cell fixation (Richard et al., 2003). In this study, no
differences were evident in the fluorescence distribution of
transduced PEP-1-FK506BP in unfixed and fixed cells. These
results demonstrate that cell fixation with paraformaldehyde
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Figure 2. PEP-1-FK506BP-mediated inhibitory effects on TNF-a/IFN-c-induced NF-jB, MAPK, and cytokine/chemokine expression in HaCaT Cells. HaCaT
cells were stimulated with TNF-a (10 ngml1) and IFN-g (10 ngml1) for 15minutes with or without pretreatment with PEP-1-FK506BP for 1 h. (a) DNA-binding
activity of NF-kB in the nuclear extracts of cells was measured by EMSA and band intensity by densitometer. (b) Phosphorylation and degradation of IkBa
were analyzed by western blotting. (c) Extracts from cells prepared and analyzed for MAPK protein activation by western blotting. (d) Total RNA was extracted,
and mRNAs for various cytokines were analyzed by RT-PCR using specific primers. (e) Cells were stimulated with TNF-a (10 ngml1) and IFN-g (10 ngml1)
for 24 hours. The culture medium of cells was harvested, after which protein production was measured by ELISA. Lanes are as follows: lane 1, control; lane 2,
TNF-a (10 ngml1) and IFN-g (10 ngml1)-treated cells; lane 3, PEP-1-FK506BP (0.1 mM)-treated cells; lane 4, PEP-1-FK506BP (0.3 mM)-treated cells; lane 5,
PEP-1-FK506BP (0.5 mM)-treated cells; lane 6, FK506BP (0.5 mM)-treated cells. EMSA, electromobility shift assay; ERK, extracellular signal-related kinase;
FK506BP, FK506-binding protein 12; JNK, c-Jun N-terminal kinase; MAPK, mitogen-activated protein kinase; MDC, macrophage-derived chemokine;
RT-PCR, reverse transcription-PCR; TNF-a, tumor necrosis factor-a.
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is not required for PEP-1-FK506BP transduction. In addition,
purified PEP-1-FK506BP was efficiently transduced into
HaCaT cells.
Both TNF-a and IFN-g synergistically induce cytokine
production in human keratinocytes and in HaCaT cells,
which might have a role in the development of AD
(Vestergaard et al., 2000). Appropriately, the role of PEP-1-
FK506BP in suppressing the production of TARC, CXCL9,
CXCL10, MDC, IL-6, and IL-1b in TNF-a/IFN-g-stimulated
HaCaT cells was examined. Transduced PEP-1-FK506BP
significantly suppressed TNF-a/IFN-g-induced cytokine and
chemokine expression levels in a dose-dependent manner.
NF-kB is a transcription factor that controls a number of
genes that are important for immunity and inflammation
(Barnes and Karin, 1997; Yun et al., 2008). The p50/p65
heterodimer is the most common dimer found in the NF-kB
signaling pathway (Verma et al., 1995). Activation of the
NF-kB signaling cascade results in phosphorylation-mediated
degradation of IkB. The present results offer firm evidence
that transduced PEP-1-FK506BP inhibits phosphorylation and
subsequent degradation of IkB. PEP-1-FK506BP suppressed
p65 NF-kB translocation to the nucleus and modulated
binding activity. Previous studies have determined that
TNF-a/IFN-g stimulation of keratinocytes activates several
intracellular signaling pathways, such as the extracellular
signal-related kinase-1/2, JNK, and p38 MAPK pathways.
Appropriately, the signal pathway in TNF-a/IFN-g-stimulated
HaCaT cells was examined. Transduced PEP-1-FK506BP
inhibited TNF-a/IFN-g-induced phosphorylation of p38 and
JNK, but not that of extracellular signal-related kinase. Lee
et al. (1994) demonstrated that the p38 kinase acts as a
specific target for a class of cytokine-suppressive anti-
inflammatory drugs, which to our knowledge is previously
unreported, and has a key role in this regulation. Both the
previous and the present results support the suggestion that
the NF-kB and MAPK (p38 and JNK) pathways are capable of
modulating the suppression of TNF-a/IFN-g-induced cytokine
and chemokine expressions by PEP-1-FK506BP.
The NC/Nga mouse model is well known as one of the
most valuable mouse models representing human AD. In
addition, this model has been used for the evaluation of drug
candidates developed for treatment of AD (Sasakawa et al.,
2001; Matsuoka et al., 2003; Gao et al., 2004). The current
results clearly demonstrate that repeated topical application
of DNFB results in AD-like skin lesions in NC/Nga mice.
However, topical application of PEP-1-FK506BP significantly
inhibits AD-like skin lesions induced by DNFB. These results
suggest that PEP-1-FK506BP may be a promising topical
agent for patients with AD.
The pathogenesis of AD causes systemic immunological
dysfunction that leads to Th1 and Th2 imbalance, which can
differently alter the secretion of cytokines (Leung et al., 2004;
Allam et al., 2005; Boguniewica and Leung, 2006). There-
fore, it is important to consider the balance of Th1 and Th2
in AD patients. It is well known that AD is a chronically
relapsing inflammatory skin disorder, and the clinical
phenotype of AD has been classified into extrinsic and
intrinsic types, so called allergic and non-allergic types,
respectively, because AD has various causes and aspects of
pathogenesis. In addition, the incidence of extrinsic and
intrinsic AD wasB80 versus 20% in many countries (Novak
and Bieber, 2003; Tokura, 2010). In general, intrinsic AD is
well characterized by normal IgE levels, lower expression of
IL-4 and IL-5, normal skin-barrier functions, and not
Protein and drug
treatment
1 2 3 4
KilledDNFBDNFBDNFBDNFB
Control PEP-1-FK506BPAD mouse
Protein and drug
treatment
Protein and drug
treatment
Protein and drug
treatment
5 (weeks)
Figure 3. Schedule for DNFB-induced atopic dermatitis in NC/Nga mice and administration of PEP-1-FK506BP. (a) DNFB (0.15%, 150ml) in
acetone/olive oil (3:1) was applied to denuded sections of the back of mice four times at 7-day intervals. PEP-1–FK506BP fusion proteins (5 mM) or the protopic
compound were topically applied to the same area of mice three times a week for 4 weeks. (b) Macroscopic observations of skin lesions in PEP-1–FK506BP
fusion protein-treated NC/Nga mice. DNFB, 2,4-dinitrofluorobenzene; FK506BP, FK506-binding protein 12; NC/Nga, Nishiki-nezumi Cinnamon/Nagoya.
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sensitized with allergens. Although the intrinsic types of AD
share features of extrinsic AD, it is different from extrinsic AD
(Tokura, 2010). However, a majority of AD have been
associated with extrinsic types of AD because of allergic
factors. Furthermore, AD patients have increased expression
of Th2 cytokines (TARC, MDC, IL-4, and IL-5) and increased
serum IgE levels (Yamada et al., 1995; Wollenberg et al.,
2000; Abramovits, 2005; Beltrani, 2005). Tanaka et al. (2007)
suggested that topical application is preferred over oral
administration for treatment of AD to avoid any unexpected
side effects. Other studies have also shown that an ointment
applied locally to skin lesions in AD animal models markedly
improved the clinical symptoms of severe AD without any
significant side effects (Tanaka et al., 2007; Oshio et al.,
2009). This study examined the effects of PEP-1-FK506BP on
the expression of Th2 cytokine expression levels and serum
IgE levels in NC/Nga mice. PEP-1-FK506BP markedly
inhibited DNFB-induced IgE levels and Th2 cytokine levels
in NC/Nga mice. Kawasaki et al. (2001) demonstrated that
TARC antibody therapy reduces the development of allergic
airway inflammation and hyperresponsiveness. Thus, TARC
may be an important mediator that exaggerates AD. These
results indicate that Th2 cytokines (TARC, MDC, IL-4, and
IL-5) participate in the pathogenesis of AD-like lesions in
NC/Nga mice. In addition, these cytokines could be targets
for therapy of AD. Therefore, we suggest that PEP-1-FK506BP
may have a potential therapeutic treatment of AD.
In summary, this study demonstrates that transduced PEP-
1-FK506BP significantly inhibits the expression of cytokines,
as well as the activation of NF-kB and MAPK in HaCaT cells.
Furthermore, topical application of PEP-1-FK506BP to NC/
Nga mice markedly inhibits AD-like skin lesions, serum IgE
levels, and the expression of cytokines. Therefore, PEP-1-
FK506BP may be a potential therapeutic agent for AD.
MATERIALS AND METHODS
Expression and purification of the PEP-1–FK506BP fusion
protein
A PEP-1 expression vector was prepared as described previously
(Eum et al., 2004). On the basis of the cDNA sequence of human
FK506BP, sense and antisense primers were synthesized and PCR
was performed. The primer sequences used are listed in Supple-
mentary Table S1 online. The PCR product was ligated into a
TA-cloning vector and a PEP-1 vector using T4 DNA ligase,
and cloned in Escherichia coli DH5a cells. In addition, a control
FK506BP was constructed that expressed the FK506BP fusion
protein without PEP-1.
To produce PEP-1–FK506BP fusion proteins, a plasmid was
transformed into E. coli BL21 cells and grown in 100ml of Luria-
Bertani media at 371C to an optimal density at a 600 nm value of
0.5–1.0 and induced with 0.5mM isopropyl-b-D-thio-galactoside at
371C for 3–4 hours. Harvested cells were lysed by sonication at 41C,
and clarified cell extracts were purified using a nickel ion-
nitrilotriacetic acid Sepharose affinity column and PD-10 column
chromatography according to the manufacturer’s instructions.
Protein concentration was estimated by the procedure by Bradford
(1976) using bovine serum albumin as a standard.
Cell culture and transduction of the PEP-1–FK506BP fusion
protein
HaCaT cells were cultured in DMEM supplemented with 10% fetal
bovine serum and antibiotics (100 mgml1 streptomycin and
100Unitsml1 penicillin) at 371C under humidified conditions of
95% air and 5% CO2. For transduction of PEP-1-FK506BP, HaCaT
cells were grown to confluence in wells of a 6-well plate. After cells
were treated with various concentrations of PEP-1-FK506BP for
1 hour, they were treated with trypsin-EDTA and washed with
phosphate-buffered saline (PBS). Cells were harvested for prepara-
tion of cell extracts to perform western blot analysis.
Fluorescence analysis
After purification of PEP-1-FK506BP, FITC labeling was carried out
according to the manufacturer’s instructions (Pierce, Rockford, IL),
and cells were grown on glass coverslips and treated with 0.5 mM of
PEP-1–FK506BP fusion proteins. After incubation for 1 hour at 371C,
cells were washed twice with PBS and trypsin-EDTA, and fixed with
Control
DNFB
PEP-1-FK506BP
Protopic
PEP-1-FK506BP
+ protopic
FK506BP
H&E stain Toluidine blue stain
Figure 4. Histological features of NC/Nga mice treated with PEP-1-
FK506BP. Atopic dermatitis was induced by repeated topical application of
DNFB with or without pretreatment with PEP-1-FK506BP. Tissue samples
were excised from the back of each mouse after 4 weeks. Tissue sections were
stained with (a) hematoxylin and eosin and (b) toluidine blue. Bars¼100 mm.
DNFB, 2,4-dinitrofluorobenzene; FK506BP, FK506-binding protein 12; H&E,
hematoxylin and eosin; NC/Nga, Nishiki-nezumi Cinnamon/Nagoya.
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4% paraformaldehyde for 10minutes at room temperature. The
distribution of fluorescence was analyzed using a fluorescence
microscope (Carl Zeiss, Jena, Germany).
Flow cytometry
HaCaT cells (2 105 cells per well) were plated in wells of 6-well
plates and grown to 90% confluence. PEP-1-FK506BP was added to
the culture medium for 1 hour. After removing the culture medium,
cells were treated with trypsin and washed with ice-cold PBS to
remove nonspecific extracellular proteins bound to the cell surface.
Cells were suspended in 0.5ml PBS and analyzed for fluorescence
using Guava Easy Cyte (GE Healthcare, Buckinghamshire, UK)
according to the manufacturer’s instructions. A total of 10,000 cells
were analyzed for each sample.
Subcellular fractionation of transduced cells
Nuclear and cytosolic fractions were prepared as described
previously (Nare et al., 1999; Park et al., 2002). Transduced HaCaT
cells were washed with PBS, acid washed with 0.2 M glycine-HCl,
pH 2.2, and trypsinized for 10minutes at 371C. Cells were harvested
after washing with cold PBS and pelleted. Cells were then
resuspended in 1ml of NP-40 buffer by gentle pipetting and
incubated on ice for 10minutes. Cells were spun through a sucrose
cushion at 1,000 g for 10minutes and cytosolic fractions collected
from the supernatants. Pellets were washed with 1ml NP-40 buffer
to completely remove cytosolic fractions. The nuclei were lysed in a
lysis buffer (50ml Tris-HCl, pH 8.0, 150mM NaCl, 0.02% sodium
azide, 100 mgml1 phenylmethylsulfonyl fluoride, 1% Triton X-100).
The resulting nuclear and cytosolic lysates were analyzed by western
blotting.
Western blot analysis
Sample proteins were electrophoretically transferred to a nitrocellu-
lose membrane, after which the membrane was blocked in 5%
nonfat milk in Tris-buffered saline (20mM Tris, 0.2 M NaCl, pH 7.5)
containing 0.05% Tween-20 for 2 hours. The membrane was
incubated for 1 hour at room temperature with anti-histidine
antibody (Santa Cruz Biotechnology, Santa Cruz, CA; dilution
1:400) in Tris-buffered saline containing Tween-20. After washing,
the membrane was incubated for 1 hour with a proper secondary
antibody conjugated to horseradish peroxidase diluted 1:10,000 in
Tris-buffered saline containing Tween-20. The membrane was
incubated with a chemiluminescent substrate and exposed to
Hyperfilm ECL (Amersham Biosciences, Piscataway, NJ). The same
membrane was stripped and re-probed with an anti-actin antibody
(cytosolic marker; Oncogene, Cambridge, MA) or an anti-poly
(ADP-ribose) polymerase antibody (nuclear marker; Biomol,
Plymouth Meeting, PA).
Measurement of protein production
HaCaT cells were exposed to TNF-a (10 ngml1) and IFN-g
(10 ngml1) in the presence or absence of PEP-1-FK506BP for
24 hours, and protein levels of cytokine and chemokine in the
supernatants were measured using ELISA kits (R&D Systems,
Minneapolis, MN).
Electromobility shift assay
HaCaT cells were pretreated with PEP-1-FK506BP for 60minutes
before TNF-a (10 ngml1) and IFN-g (10 ngml1) treatment for
15minutes, after which nuclear extracts of HaCaT cells were
prepared and analyzed for NF-kB-binding activity by electromobility
shift assay as described previously (Song et al., 2008). An NF-kB
consensus oligonucleotide (Promega, Madison, WI) was used in
the assay. The complementary oligonucleotide was annealed
and end labeled with [g-32P] ATP using T4 polynucleotide kinase.
The electromobility shift assay was performed in a total volume of
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Figure 5. Inhibitory effect of PEP-1-FK506BP on serum IgE levels in NC/Nga
mice. AD was induced by repeated topical application of DNFB with or
without pretreatment with PEP-1-FK506BP. The serum levels of IgE in NC/Nga
mice were measured by ELISA. *Po0.05 compared with mice treated with
DNFB alone. Lanes are as follows: lane 1, control; lane 2, DNFB; lane 3, PEP-
1-FK506BP; lane 4, protopic; lane 5, PEP-1-FK506BPþprotopic; lane 6,
FK506BP. AD, atopic dermatitis; DNFB, 2,4-dinitrofluorobenzene; FK506BP,
FK506-binding protein 12; NC/Nga, Nishiki-nezumi Cinnamon/Nagoya.
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Figure 6. Inhibitory effect of PEP-1-FK506BP on DNFB-induced cytokines in
NC/Nga mice. AD was induced by repeated topical application of DNFB with
or without pretreatment with PEP-1-FK506BP. Total RNA was extracted from
lymph nodes in NC/Nga mice. Cytokine mRNA was analyzed by RT-PCR
using specific primers. Lanes are as follows: lane 1, control; lane 2, DNFB;
lane 3, PEP-1-FK506BP; lane 4, protopic; lane 5, PEP-1-FK506BPþ protopic;
lane 6, FK506BP (lane 6 of TARC and MDC were not run consecutively). AD,
atopic dermatitis; DNFB, 2,4-dinitrofluorobenzene; FK506BP, FK506-binding
protein 12; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; MDC,
macrophage-derived chemokine; NC/Nga, Nishiki-nezumi Cinnamon/
Nagoya; RT-PCR, reverse transcription-PCR; TARC, thymus and activation-
regulated chemokine.
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40 ml at 371C. Overall, 10 mg of nuclear extracts was equilibrated for
15minutes in a binding buffer (10mM Tris-HCl, pH 8.0, 75mM KCl,
2.5mM MgCl2, 0.1mM EDTA, 10% glycerol, 0.25mM diothiothreitol)
and 1 mg of poly dI/dC. A 32P-labeled oligonucleotide probe
(20,000 c.p.m.) was then added and the reaction incubated at
371C for an additional 30minutes. Both bound and free DNA were
then resolved by electrophoresis on a 6% native polyacrylamide gel
in TBE buffer (89mM Tris-HCl, 89mM boric acid, and 2mM EDTA).
Reverse transcription-PCR analysis
After total RNA was isolated from cells using a Trizol reagent kit
(Invitrogen, Carlsbad, CA) according to the manufacturer’s instruc-
tions, RNA (2mg) was reversibly transcribed with reverse transcrip-
tase and oligo-(dT) primer. PCR amplification of TARC, CXCL9,
CXCL10, MDC, IL-1b, IL-6, and b-actin cDNA aliquots was
performed with the following sense and antisense primers. All the
primer sequences used are listed in Supplementary Table S1 online.
PCR was performed using a PCR premix kit (Intron Biotechnology,
Seoul, Korea) for each primer and was terminated by heating to 721C
for 5minutes. PCR products were resolved on a 1% agarose gel and
visualized with ultraviolet light after ethidium bromide staining.
Induction and histology of AD-like skin lesions
Female 6-week-old NC/Nga mice were purchased from the Joong-
Ang Experimental Animal Center (Seoul, Korea). All experimental
procedures involving animals and their care conformed to the Guide
for the Care and Use of Laboratory Animals of the National
Veterinary Research and Quarantine Service of Korea and were
approved by the Hallym Medical Center Institutional Animal Care
and Use Committee (Permit number: Hallym 2009-30). AD was
induced by the topical application of 150 ml of 0.15% DNFB in
acetone/olive oil (3:1) to the hair-removed back of mice four times at
7-day intervals. PEP-1-FK506BP (5mM) and protopic were topically
applied to the same area on mice three times per week for 4 weeks.
Mice (n¼ 20 per group) were killed and blood was collected from
the vena cava. Skin tissues from the backs of mice were excised and
subjected to histological examination. The serum levels of IgE in
NC/Nga mice were quantified using a mouse IgE ELISA (Bethyl
Laboratories, Montgomery, TX) according to the manufacturer’s
instructions.
For histological analysis, skin biopsies were fixed in 4%
paraformaldehyde, embedded in paraffin, sectioned at a thickness
of 5mm, and stained with hematoxylin and eosin and toluidine blue.
Stained tissue sections were examined to analyze the infiltration of
inflammatory cells using standard bright-field optics (Carl Zeiss).
Statistical analyses
Data are presented as mean±SD. Comparison between the groups
was made with analysis of variance, followed by Dunnett’s test. A
value of Po0.05 was considered statistically significant.
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